Results 181 to 190 of about 7,836,429 (310)

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia

Clinical Cancer Research, 2016
K. Pratz, M. Rudek, I. Gojo, M. Litzow, M. McDevitt, J. Ji, L. Karnitz, J. Herman, R. Kinders, B. Smith, S. Gore, H. Carraway, M. Showel, D. Gladstone, M. Levis, H. Tsai, G. Rosner, A. Chen, S. Kaufmann, J. Karp   +19 more
semanticscholar   +1 more source

Neuro-reproductive toxicity and carcinogenicity of 1-bromopropane: studies for evidence-based preventive medicine. [PDF]

J Occup Health
Ichihara G.
europepmc   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Recurrent late-onset neutropenia after ofatumumab treatment in a case of multiple sclerosis. [PDF]

Neurol Res Pract
Chen J, Burmeister T, Frankenstein L, Laumeier I, Siffrin V.   +4 more
europepmc   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

A single centre experience of patients with rare cancers referred for early phase clinical trials. [PDF]

BMC Cancer
Angelakas A, Cook N, Graham DM, Krebs M, Thistlethwaite F, Carter L.   +5 more
europepmc   +1 more source

EXPERIMENTAL PRODUCTION OF ACUTE AND CHRONIC ARTHRITIS AND ARTICULAR NEOPLASM BY RADIUM [PDF]

BMJ, 1927
openaire   +3 more sources

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Identification of a novel <i>NRF1</i>::<i>PDGFRA</i> fusion in myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions. [PDF]

Front Oncol
Liu J, Feng Y, Zhang Y, Xiao Y, Liu X, Xiao T, Zou J, Fan K, Lu L, Yang X, Gong J.   +10 more
europepmc   +1 more source

Blood signals: from birth to disease and death

, 2014
Bowman, T., Flores-Figueroa, E., King, K., Kokkaliaris, K., Lessard, J., Trompouki, E., Will, B.   +6 more
core   +1 more source